New Four-Year Data Demonstrate Rezand#363;m(TM) Water Vapor Therapy Offers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms

MARLBOROUGH, Mass., Jan. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced that data from a randomized clinical trial demonstrate that Rezūm Water Vapor Therapy, a minimally invasive trea... Devices, Urology Boston Scientific, Water Vapor Therapy, benign prostatic hyperplasia

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044707

Source: HSMN NewsFeed - January 25, 2019 Category: Pharmaceuticals Source Type: news

More News: Benign Prostatic Hyperplasia | Clinical Trials | Marketing | Pharmaceuticals | Urology & Nephrology